MOLCURE Inc. today announced that it has entered into a multi-year strategic research agreement with Boehringer Ingelheim for the discovery of innovative antibody therapeutics for multiple targets using MOLCURE’s proprietary AI-driven platform technology.

For more details, please see the full press release at the link below.

Link: https://www.biotechnewswire.ai/202510072691/molcure-joins-forces-with-boehringer-ingelheim-to-discover-and-develop-innovative-antibody-drugs-for-multiple-targets-using-its-ai-driven-platform-technology.html